Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has issued an announcement.
Newron Pharmaceuticals has secured a new European compound patent, EP4615820, covering the crystalline forms, manufacturing processes and uses of its lead schizophrenia drug candidate Evenamide, extending intended product exclusivity in the EU to 2044 and further strengthening its intellectual property position around the asset. The patent win underpins Newron’s strategy to maximize the therapeutic and commercial potential of Evenamide, which is in a pivotal global phase III program (ENIGMA‑TRS) targeting at least 1,000 patients with treatment‑resistant or poorly responsive schizophrenia, a large, high‑morbidity population for whom current dopamine‑focused antipsychotics are often insufficient; by reinforcing long-term protection in Europe and with corresponding filings in major markets, the company bolsters its competitive footing in CNS drug development and enhances the prospective value of Evenamide to patients, partners and investors if late‑stage trials succeed.
The most recent analyst rating on (CH:NWRN) stock is a Buy with a CHF26.00 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals is a biopharmaceutical company headquartered near Milan, Italy, specializing in neuroscience-based therapies for central and peripheral nervous system diseases. Its lead asset, Evenamide, is a novel glutamate modulator being developed as an add-on treatment for treatment‑resistant schizophrenia, supported by development and commercialization partnerships in Asia, while its first marketed product, Xadago/Safinamide for Parkinson’s disease, is already approved and commercialized across Europe, North America, Latin America, the Middle East, Japan and South Korea through regional partners.
Average Trading Volume: 144,820
Technical Sentiment Signal: Buy
Current Market Cap: CHF476.1M
Learn more about NWRN stock on TipRanks’ Stock Analysis page.